Navigation Links
Seminar Will Bring ALS Researchers to Patient Groups
Date:2/17/2009

The Leading ALS Lab Presents on Therapy Development Strategy

CAMBRIDGE, Mass., Feb. 17 /PRNewswire-USNewswire/ -- The ALS Therapy Development Institute (ALS TDI) has announced the 2009 launch of its popular ALS Research 101 series. The two-hour, interactive seminar is designed to inform and update patients, their families and local communities on worldwide efforts to discover and develop effective treatments for amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease).

People diagnosed with this fatal disease typically succumb within three years of initial symptoms because there are no effective therapeutics to slow or stop the relentless progression. ALS TDI will offer the free seminars in a dozen cities and towns across the United States this year.

"Every day, ALS patients are bombarded with new reports and claims of breakthroughs. We aim to provide patients and their families with the tools to navigate through endless streams of information and to use that knowledge in a positive way. As researchers, we have a responsibility to help make today's scientific research approachable; conveying, for example, why therapeutic development has been challenging and what exciting prospects exist today," said John McCarty, Ph.D., an experienced biology researcher who serves as Director of Therapeutic Investigations at ALS TDI.

Dr. McCarty will be joined at each event by Mary Beth Geise, R.N., a nurse with more than 30 years experience working with ALS patients and their families. It is the team's objective to provide information on the latest research, address 'hot topics', and lead a discussion on quality of life issues. The speakers will also describe the impact a three-year, $18 million funding and scientific collaboration between ALS TDI and the Muscular Dystrophy Association's Augie's Quest initiative has had on the pace of research, as well as the recently announced 4ALS Awareness charitable campaign launched in partnership with Major League Baseball.

ALS TDI will kick off the series with an ALS Research 101 on March 28 in Orange County, California followed by stops in Salt Lake City, Utah on April 4, and Iowa City, Iowa on April 7. The Institute is also planning events in Detroit, Michigan and Seattle, Washington during the month of April; New Orleans, Louisiana in May; and Nashville, Tennessee and Denver, Colorado in June, with dates to be announced online soon. The Institute is also confirming locations for events in Green Bay, Wisconsin; Washington, D.C.; San Jose, California; New York City, New York and Boston, Massachusetts, before the end of the year. Registration is free but participants are encouraged to sign up early. Exact dates, times and locations will be announced locally, as well as online at http://www.als101.org, as they are confirmed.

For more information on the ALS Research 101 seminar series, please contact Jessica Sullivan at ALS TDI at (617) 441-7238 or via email at jsullivan@als.net. To be notified of changes to the tour, ALS community members are encouraged to sign-up for the ALS TDI monthly e-update newsletter at http://www.als.net.

About the ALS Therapy Development Institute

The ALS Therapy Development Institute (ALS TDI) (www.als.net), based in Cambridge, Mass., operates the world's largest research and development program focused exclusively on ALS. The Institute has a staff of more than 30 scientists and research technicians, working on behalf of ALS patients to discover and advance novel therapeutics for treating, and ultimately curing, ALS. The nonprofit biotechnology institute excels in identifying novel disease targets, discovering compounds that may act against these targets, and screening potential treatments for clinical development.

About Augie's Quest

Fitness pioneer Augie Nieto started Augie's Quest (www.augiesquest.org) in conjunction with MDA's ALS Division. Nieto is co-founder and former president of Life Fitness of Chicago, and chairman of Octane Fitness. He and his wife, Lynne, serve as co-chairpersons of MDA's ALS Division. Nieto received a diagnosis of ALS in March 2005.

About MDA

MDA (www.mda.org) is the world's largest provider of ALS services and funder of ALS research. Over the years, it has expended $230 million in this effort. It operated 225 clinics across the county, 38 of which are ALS-specific research and care centers.

Media Contact: Robert Goldstein, ALS TDI, 617.441.7295, rgoldstein@als.net


'/>"/>
SOURCE ALS Therapy Development Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Alliance Biosciences Announces Trade Mission to Singapore with Speaker Presentation at International Lab Design Seminar
2. World Leader in Bench Top Flow Chemistry Instruments ThalesNano, Inc. Introduces an Industry First Seminar Series
3. The Michigan Life Sciences Pipeline Announces New Best Practices Seminars Tailored to Michigan Businesses
4. Netsmart Technologies Web Seminar Helps Behavioral Health Organizations Understand Electronic Prescribing and the Importance of New Medicare-Related E-Prescribing Legislation
5. First-Ever Cancer and Careers Seminar Debuts in Orange County
6. Pharsight to Present at ROeS Seminar in Bern, Switzerland on September 10 & 11, 2007
7. Immune Targeting Systems Completes Second Tranche of Series-A Funding Bringing Total Funds Raised to More Than GBP5m
8. Smallest ever quantum dots bring real world applications closer
9. U of T chemistry discovery brings organic solar cells a step closer
10. Cellectricon Partners With The Automation Partnership - Bringing Next Generation Ion Channel Screening System to Market.
11. Alfred Mann Foundation for Biomedical Engineering Launches New Web Site Designed to Help University Researchers Bring Biomedical Advances to Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... 28, 2017 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB:REPCF) ... regenerative medicine company developing unique biologic products for pattern ... chronic tendon degeneration, today announced it has recently signed ... committed to work with RepliCel to get the Company,s ... ...
(Date:2/28/2017)... -- The Biotech industry is today,s focus on ... ZIOPHARM Oncology Inc. (NASDAQ: ZIOP ), Aurinia Pharmaceuticals ... ARNA ), and Marinus Pharmaceuticals Inc. (NASDAQ: ... which was narrowly mixed on Monday, February 27 th , ... 0.1%, while shares of health care companies in the S&P ...
(Date:2/27/2017)... - InMed Pharmaceuticals, Inc. ("InMed") (CSE: IN; OTCQB: IMLFF), reported ... 2017 a total of 10,672,750 common share purchase warrants have ... Proceeds from the exercise of these warrants totalled $1,387,458 and ... ... for this expression of confidence by our warrant holders. This ...
(Date:2/27/2017)... and HAMILTON, Bermuda ... (NASDAQ: ADXS ) and ... companies focused on developing cancer immunotherapies, today announced ... develop a novel cancer immunotherapy agent using Advaxis, ... SELLAS, patented WT1 targeted heteroclitic peptide antigen mixture ...
Breaking Biology Technology:
(Date:2/8/2017)... NEW YORK , Feb. 7, 2017 /PRNewswire/ ... point. Driven largely by the confluence of organizations, ... users, distaste for knowledge-based systems (password and challenge ... consumer, industrial, and government systems. The market is ... been a demarcation between consumer and enterprise uses ...
(Date:2/7/2017)... , Feb. 7, 2017   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... , its innovative, highly flexible and award winning eClinical ... customers. iMedNet is a proven Software-as-a-Service (SaaS) ... Data Capture (EDC), but also delivers an entire suite ...
(Date:2/7/2017)... New York , February 7, 2017 ... as ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or ... management and electronic transaction processing services, is pleased to ... of the Company. Effective January 31, 2017, ... the Board of Directors, CEO and President.  An experienced ...
Breaking Biology News(10 mins):